As a proof of concept, to investigate the potential usefulness of the TG2-inhibitors under study, human monocyte-derived macrophages (hMDM) were infected with Mtb and then treated with cystamine, cysteamine alone, or in combination with the second-line anti-TB drug capreomycin. This evidence concerns the gene TGM2 and tuberculosis.